Simplify Asset Management Inc. Takes Position in Twist Bioscience Co. (NASDAQ:TWST)

Simplify Asset Management Inc. bought a new position in shares of Twist Bioscience Co. (NASDAQ:TWST) during the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor bought 25,471 shares of the company’s stock, valued at approximately $1,255,000.

Several other institutional investors have also recently bought and sold shares of TWST. Artisan Partners Limited Partnership raised its holdings in shares of Twist Bioscience by 111.3% in the fourth quarter. Artisan Partners Limited Partnership now owns 3,723,305 shares of the company’s stock valued at $137,241,000 after purchasing an additional 1,961,621 shares during the last quarter. Victory Capital Management Inc. raised its position in Twist Bioscience by 4,133.1% in the second quarter. Victory Capital Management Inc. now owns 308,171 shares of the company’s stock worth $15,187,000 after acquiring an additional 300,891 shares during the period. Norges Bank purchased a new position in Twist Bioscience in the fourth quarter valued at about $10,766,000. Dimensional Fund Advisors LP increased its stake in shares of Twist Bioscience by 29.0% during the 4th quarter. Dimensional Fund Advisors LP now owns 1,267,708 shares of the company’s stock worth $46,732,000 after purchasing an additional 284,884 shares during the last quarter. Finally, Baillie Gifford & Co. grew its holdings in Twist Bioscience by 12.1% during the first quarter. Baillie Gifford & Co. now owns 1,227,528 shares of the company’s stock valued at $42,116,000 after purchasing an additional 132,770 shares during the period.

Analyst Ratings Changes

Several research analysts have recently weighed in on TWST shares. Robert W. Baird increased their price target on Twist Bioscience from $40.00 to $46.00 and gave the stock an “outperform” rating in a research note on Monday, August 5th. Guggenheim began coverage on shares of Twist Bioscience in a report on Tuesday, June 4th. They issued a “buy” rating and a $53.00 price objective for the company. Barclays dropped their target price on Twist Bioscience from $60.00 to $55.00 and set an “overweight” rating on the stock in a research report on Monday, August 5th. JPMorgan Chase & Co. lifted their price objective on Twist Bioscience from $28.00 to $35.00 and gave the company an “underweight” rating in a research note on Monday, August 5th. Finally, TD Cowen raised their price target on Twist Bioscience from $55.00 to $65.00 and gave the company a “buy” rating in a report on Thursday, June 13th. One equities research analyst has rated the stock with a sell rating and eight have issued a buy rating to the stock. According to MarketBeat, Twist Bioscience currently has an average rating of “Moderate Buy” and an average target price of $48.22.

Twist Bioscience Stock Performance

Twist Bioscience stock opened at $47.99 on Friday. Twist Bioscience Co. has a fifty-two week low of $14.42 and a fifty-two week high of $60.90. The stock has a market cap of $2.81 billion, a price-to-earnings ratio of -14.28 and a beta of 1.76. The stock’s 50 day simple moving average is $47.41 and its two-hundred day simple moving average is $42.95.

Twist Bioscience (NASDAQ:TWST) last released its earnings results on Friday, August 2nd. The company reported ($1.47) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.76) by ($0.71). Twist Bioscience had a negative return on equity of 32.17% and a negative net margin of 74.63%. The business had revenue of $81.50 million during the quarter, compared to analysts’ expectations of $77.40 million. During the same period in the prior year, the company earned ($1.01) earnings per share. The firm’s quarterly revenue was up 27.7% compared to the same quarter last year. On average, analysts predict that Twist Bioscience Co. will post -3.13 earnings per share for the current year.

Insider Transactions at Twist Bioscience

In other Twist Bioscience news, CFO Adam Laponis sold 842 shares of Twist Bioscience stock in a transaction on Tuesday, July 9th. The stock was sold at an average price of $48.91, for a total value of $41,182.22. Following the completion of the sale, the chief financial officer now owns 73,602 shares of the company’s stock, valued at approximately $3,599,873.82. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. In related news, CFO Adam Laponis sold 842 shares of the stock in a transaction that occurred on Tuesday, July 9th. The shares were sold at an average price of $48.91, for a total transaction of $41,182.22. Following the transaction, the chief financial officer now owns 73,602 shares in the company, valued at $3,599,873.82. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, SVP Paula Green sold 1,137 shares of the firm’s stock in a transaction that occurred on Monday, August 5th. The stock was sold at an average price of $39.93, for a total transaction of $45,400.41. Following the completion of the sale, the senior vice president now owns 88,837 shares in the company, valued at approximately $3,547,261.41. The disclosure for this sale can be found here. Insiders have sold a total of 15,125 shares of company stock valued at $664,784 in the last ninety days. 3.92% of the stock is currently owned by corporate insiders.

Twist Bioscience Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.